Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
PLoS One. 2012;7(12):e49422. doi: 10.1371/journal.pone.0049422. Epub 2012 Dec 12.
Mouse models possessing green fluorescent protein (GFP) and/or human aldose reductase (hAR) in vascular tissues have been established and crossed with naturally diabetic Akita mice to produce new diabetic mouse models.
Colonies of transgenic C57BL mice expressing GFP (SMAA-GFP), hAR (SMAA-hAR) or both (SMAA-GFP-hAR) in vascular tissues expressing smooth muscle actin were established and crossbred with C57BL/6-Ins2(Akita)/J (AK) mice to produce naturally diabetic offspring AK-SMAA-GFP and AK-SMAA-GFP-hAR. Aldose reductase inhibitor AL1576 (ARI) was administered in chow. Retinal and lenticular sorbitol levels were determined by HPLC. Retinal functions were evaluated by electroretinography (ERGs). Growth factor and signaling changes were determined by Western Blots using commercially available antibodies. Retinal vasculatures were isolated from the neural retina by enzymatic digestion. Flat mounts were stained with PAS-hematoxylin and analyzed.
Akita transgenics developed DM by 8 weeks of age with blood glucose levels higher in males than females. Sorbitol levels were higher in neural retinas of AK-SMAA-GFP-hAR compared to AK-SMAA-GFP mice. AK-SMAA-GFP-hAR mice also had higher VEGF levels and reduced ERG scotopic b-wave function, both of which were normalized by AL1576. AK-SMAA-GFP-hAR mice showed induction of the retinal growth factors bFGF, IGF-1, and TGFβ, as well as signaling changes in P-Akt, P-SAPK/JNK and P-44/42 MAPK that were also reduced by ARI treatment. Quantitative analysis of flat mounts in 18 week AK-SMAA-GFP-hAR mice revealed increased loss of nuclei/capillary length and a significant increase in the percentage of acellular capillaries present which was not seen in AK-SMAA-GFP-hAR treated with ARI.
CONCLUSIONS/SIGNIFICANCE: These new mouse models of early onset diabetes may be valuable tools for assessing both the role of hyperglycemia and AR in the development of retinal lesions associated with diabetic retinopathy.
已建立并交叉繁殖了在血管组织中表达绿色荧光蛋白 (GFP) 和/或人醛糖还原酶 (hAR) 的携带 GFP 和/或 hAR 的小鼠模型,使其与自然发生糖尿病的 Akita 小鼠交配,以产生新的糖尿病小鼠模型。
建立了在血管组织中表达平滑肌肌动蛋白的 C57BL 转基因小鼠品系,表达 GFP(SMAA-GFP)、hAR(SMAA-hAR)或两者(SMAA-GFP-hAR),并与 C57BL/6-Ins2(Akita)/J (AK) 小鼠交配,以产生自然发生糖尿病的后代 AK-SMAA-GFP 和 AK-SMAA-GFP-hAR。通过饲料给予醛还原酶抑制剂 AL1576(ARI)。通过 HPLC 测定视网膜和晶状体山梨醇水平。通过视网膜电图 (ERG) 评估视网膜功能。使用商业可得的抗体通过 Western Blot 确定生长因子和信号变化。通过酶消化从神经视网膜分离视网膜血管,并用 PAS-hematoxylin 染色并进行分析。
8 周龄时,Akita 转基因出现 DM,雄性血糖水平高于雌性。与 AK-SMAA-GFP 小鼠相比,AK-SMAA-GFP-hAR 小鼠的神经视网膜山梨醇水平更高。AK-SMAA-GFP-hAR 小鼠的 VEGF 水平也更高,暗适应 ERG 次波功能降低,这两种情况均可通过 AL1576 得到纠正。AK-SMAA-GFP-hAR 小鼠显示视网膜生长因子 bFGF、IGF-1 和 TGFβ 的诱导,以及 P-Akt、P-SAPK/JNK 和 P-44/42 MAPK 的信号变化,这些变化也可通过 ARI 治疗得到降低。对 18 周龄 AK-SMAA-GFP-hAR 小鼠的平片进行定量分析显示,核/毛细血管长度的损失增加,无细胞毛细血管的比例显著增加,而在用 ARI 治疗的 AK-SMAA-GFP-hAR 中未观察到这种情况。
结论/意义:这些早期发病糖尿病的新型小鼠模型可能是评估高血糖和 AR 在与糖尿病视网膜病变相关的视网膜病变发展中作用的有价值的工具。